Syndax Pharmaceuticals (SNDX) Misses Q3 EPS by 13c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.84), $0.13 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline
• NAPCO Security Tech (NSSC) Tops Q4 EPS by 11c